整个蛋白质组的分析揭示了结肠直肠癌的潜在治疗点:一项两样本的门德尔随机化研究
Yi-Xin Cai1, Yi-Qing Wu2, Jie Liu3
1Zhejiang Provincial Clinical Research Center for Pediatric Disease, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
BMC cancer
|December 4, 2023
概括
这项研究确定了23种与结直肠癌 (CRC) 有因果关系的血蛋白,提供了新的治疗点. 这些发现促进了对CRC发展和潜在干预措施的理解.
科学领域:
- 遗传学和基因组学 在
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 结肠直肠癌 (CRC) 仍然是癌症死亡的重要原因,需要新的治疗策略.
- 确定分子点对于开发更有效的CRC治疗至关重要.
研究的目的:
- 调查大量血蛋白与结直肠癌 (CRC) 之间的因果关系.
- 通过分析蛋白质-CRC关系来发现CRC的潜在新型治疗点.
主要方法:
- 利用双样本的门德尔随机化 (MR) 来评估4,489个血蛋白对CRC风险的因果关系.
- 在英国生物银行 (UK Biobank) 采用调解分析来探索通过风险因素和全现象关联研究 (PWAS) 的间接影响.
主要成果:
- 确定了23种与CRC有显著因果关联的血蛋白,包括VIMP,MICB,TNFRSF11B,C5orf38和SLC5A8.8.
- 已确认的风险因素和CRC之间的已知关联,并确定了蛋白质的调解作用.
- 发现了154种与至少一种CRC风险因素有因果关系的血蛋白.
结论:
- 这项研究阐明了血蛋白和CRC之间的因果关系,增强了对CRC病原学的理解.
- 为识别和验证结直肠癌新型蛋白质基治疗点提供基础.
更多相关视频
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


